Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Diffuse Large B Cell Lymphoma Genetic Classification By Targeted Sequencing and Associations with Immunochemotherapy-Treated Patients' Clinical Outcome

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-141193

Published: 2020

Journal Articles

A Phase IIa, Open-Label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma: Long-Term Follow-up, Final Analysis

Wojciech Jurczak, MD PhD, Pier Luigi Zinzani, MD PhD, Georg Hess, Gianluca Gaidano, MD PhD, Mariano Provencio, MD, Zsolt Nagy, MD PhD, Tadeusz Robak, MD, Kami J. Maddocks, MD, Christian Buske, MD PhD, Sumeet Ambarkhane, MD MBBS, Wolfram Brugger, Maren Dirnberger-Hertweck, PhD, Sascha Tillmanns, Johannes Weirather, PhD, Kristie Blum

Blood (2019) 134 (Supplement_1): 4078.

https://doi.org/10.1182/blood-2019-124297

Published: 2019

Journal Articles

Nivolumab for Newly Diagnosed Advanced-Stage Classical Hodgkin Lymphoma (cHL): Results from the Phase 2 Checkmate 205 Study

Radhakrishnan Ramchandren, MD, Michelle A. Fanale, MD, Antonio Rueda, Philippe Armand, MD PhD, Marek Trněný, MD PhD, Tatyana A Feldman, MD, Stephen M Ansell, MD PhD, Mariano Provencio, MD, Ulrich Jaeger, MD, Jonathon B Cohen, MDMS, Kerry J Savage, BSc, MD MSc, Wolfgang Willenbacher, Mariana Sacchi, Anne Sumbul, Eva Domingo Domenech, MD

Blood (2017) 130 (Supplement 1): 651.

https://doi.org/10.1182/blood.V130.Suppl_1.651.651

Published: 2017

Journal Articles

Safety and Preliminary Antitumor Activity of the Anti-PD-1 Monoclonal Antibody REGN2810 Alone or in Combination with REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with B-Lymphoid Malignancies

Blood (2017) 130 (Supplement 1): 1495.

https://doi.org/10.1182/blood.V130.Suppl_1.1495.1495

Published: 2017

Journal Articles

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) after Treatment with Nivolumab for Relapsed/Refractory Hodgkin Lymphoma

Philippe Armand, MD PhD, Pier Luigi Zinzani, MD PhD, Graham P. Collins, MD PhD, Jonathon B. Cohen, MD, Ahmad S. Halwani, MD, Carmelo Carlo-Stella, MD, Michael M. Millenson, MD, Mariano Provencio, MD PhD, Eva Domingo Domenech, MD, Lisa Giulino Roth, MD, Luca Castagna, MD, Kazunobu Kato, MD, Mihaela Popa McKiver, Anne Sumbul, Lili Zhu, MS, Armando Santoro, MD

Blood (2016) 128 (22): 3502.

https://doi.org/10.1182/blood.V128.22.3502.3502

Published: 2016

Journal Articles

Single-Agent MOR208 in Relapsed or Refractory (R-R) Non-Hodgkin's Lymphoma (NHL): Results from Diffuse Large B-Cell Lymphoma (DLBCL) and Indolent NHL Subgroups of a Phase IIa Study

Wojciech Jurczak, MD PhD, Pier Luigi Zinzani, MD PhD, Gianluca Gaidano, MD PhD, Andre Goy, MD, Mariano Provencio, MD PhD, Zsolt Nagy, MD PhD, Tadeusz Robak, MD PhD, Kami J. Maddocks, MD, Christian Buske, Sumeet Ambarkhane, MD, Mark Winderlich, PhD, Maren Dirnberger-Hertweck, PhD, Jan Endell, PhD, Kristie A Blum, MD

Blood (2016) 128 (22): 623.

https://doi.org/10.1182/blood.V128.22.623.623

Published: 2016

Journal Articles

Phase IIa Study of Single-Agent MOR208 in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Wojciech Jurczak, Pier Luigi Zinzani, MD PhD, Gianluca Gaidano, MD PhD, Andre Goy, MD, Mariano Provencio, MD PhD, Zsolt Nagy, MD PhD, Tadeusz Robak, MD PhD, Kami J. Maddocks, MD, Christian Buske, MD, Roman Pawel Korolkiewicz, MD PhD, Frank Striebel, PhD, Kristie Blum, MD

Blood (2015) 126 (23): 1528.

https://doi.org/10.1182/blood.V126.23.1528.1528

Published: 2015

Journal Articles

Gene Rearrangements and Other Molecular Features in Aggressive B-Cell Lymphomas of Patients with and without HIV-Infection

Maria Joao Baptista, PharmD, PhD, Gustavo Tapia, MD, Ana-Maria Muñoz-Marmol, PhD, Olga Garcia, MD, Josep Muncunill, MSc, Maria-Jose Terol, MD PhD, Eva González-Barca, MD PhD, Pilar Miralles, MD PhD, Ferran Vall-Llovera, MD, Mariano Provencio, MD PhD, Miriam Moreno, MD, Juan-Manuel Sancho, MD PhD, Jose-Luis Mate, MD PhD, Evarist Feliu, MD PhD, Josep-Maria Ribera, MD PhD, Jose-Tomas Navarro, MD PhD

Blood (2015) 126 (23): 3874.

https://doi.org/10.1182/blood.V126.23.3874.3874

Published: 2015

Journal Articles

A Phase IIa, Open-Label, Multicenter Study of Single-Agent MOR00208, an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma

Kristie A. Blum, MD, Kami Maddocks, MD, Zsolt Nagy, MD, Pier Luigi Zinzani, MD PhD, Andre Goy, MD, Mariano Provencio, Tadeusz Robak, MD, Christian Buske, MD, Roman Pawel Korolkiewicz, MD, Mark Winderlich, Wojciech Jurczak, MD PhD

Blood (2014) 124 (21): 3089.

https://doi.org/10.1182/blood.V124.21.3089.3089

Published: 2014

Journal Articles

PLCG1 mutations in cutaneous T-cell lymphomas

Blood (2014) 123 (13): 2034–2043.

https://doi.org/10.1182/blood-2013-05-504308

Published: 2014

Includes: Supplemental data

Journal Articles

Risk Adapted-High Dose Therapies Modulate the Impact of Biological Classification in Diffuse Large B Cell Lymphoma Prognosis. Analysis of Biological Markers in Patients From Clinical Trials in Geltamo and Gotel Spanish Collaborative Groups.

Blood (2012) 120 (21): 2672.

https://doi.org/10.1182/blood.V120.21.2672.2672

Published: 2012

Journal Articles

Mutations in PLCG1 Is a Frequent Event in Cutaneous T-Cell Lymphomas

Blood (2012) 120 (21): 300.

https://doi.org/10.1182/blood.V120.21.300.300

Published: 2012

Journal Articles

A Prospective Study of Cardiotoxicity In Non-Hodgkin Lymphoma Patients with RAPID-Infusion Rituximab

Mariano Provencio, Antonio Sanchez, Miriam Mendez, Constanza Maximiano, Blanca Cantos, Juan A Vargas, Pablo Tutor, Susana Mellor, Miguel A. Canales, MD, PhD, Pilar España

Blood (2008) 112 (11): 4966.

https://doi.org/10.1182/blood.V112.11.4966.4966

Published: 2008

Journal Articles

Treatment of Good Prognosis CD20+ Large-Cell Lymphomas in Patients Aged 65 to 80, with 3 Cycles of R-CHOP14 Followed by An Injection of 90Y Ibritumomab Tiuxetan

Peyrade Frederic, Lepeu Gérard, Mariano Provencio, Gastaud Lauris, Fontana Xavier, Broglia Jean-Marc, Carrier Patricia, Chamorey Emmanuel, Hebert Christophe, Antoine Thyss, MD

Blood (2008) 112 (11): 4937.

https://doi.org/10.1182/blood.V112.11.4937.4937

Published: 2008

Journal Articles

Clinical Significance of the Presence of Occult CNS Involvement Assessed by Cytofluorometry in Patients with Non Hodgkin’s Lymphoma and High Risk of CNS Relapse

Juan-Manuel Sancho, Alberto Orfao, Olga García, Carlos Panizo, Elena Pérez, Mireia Morgades, Antonio Salar, José-Antonio García-Vela, Natalia Alonso, Eva González-Barca, Josefa Plaza, Dolores Caballero, Mariano Provencio, Miguel Marin, Teresa Molero, Josep-Maria Ribera

Blood (2008) 112 (11): 5270.

https://doi.org/10.1182/blood.V112.11.5270.5270

Published: 2008

Journal Articles

Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma

Blood (2006) 108 (2): 662–668.

https://doi.org/10.1182/blood-2005-12-5125

Published: 2006

Includes: Supplemental data

Journal Articles

Up-Front Treatment of Diffuse Large-B Cell Lymphoma (DLBCL) in Elderly Patients with Rituximab in Combination with CHOP-Like Chemotherapy: A Multicenter Study on the Current Clinical Management.

Miguel A. Canales, MD, PhD, Javier de la Serna, MD, Pilar Sabin, MD, Joaquin Diaz-Mediavilla, MD, Mariano Provencio, MD, Rosa Ayala, MD, Ricardo Perez, MD, Ana Alvarez, MD, Antonio Sanchez, MD, Raquel Gil, Fernando Hernandez-Navarro, MD, PhD

Blood (2005) 106 (11): 4778.

https://doi.org/10.1182/blood.V106.11.4778.4778

Published: 2005

Journal Articles

Treatment with Rituximab, CHOP and Highly Active Antiretroviral Therapy (HAART) in AIDS-Related Diffuse Large B-Cell Lymphomas (DLBCL). Study of 60 Patients.

Blood (2005) 106 (11): 774.

https://doi.org/10.1182/blood.V106.11.774.774

Published: 2005

Journal Articles

An IELSG International Survey of Primary Effusion Lymphoma (PEL).

Blood (2004) 104 (11): 3265.

https://doi.org/10.1182/blood.V104.11.3265.3265

Published: 2004

NARROW

Diffuse Large B Cell Lymphoma Genetic Classification By Targeted Sequencing and Associations with Immunochemotherapy-Treated Patients' Clinical Outcome

A Phase IIa, Open-Label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma: Long-Term Follow-up, Final Analysis

Nivolumab for Newly Diagnosed Advanced-Stage Classical Hodgkin Lymphoma (cHL): Results from the Phase 2 Checkmate 205 Study

Safety and Preliminary Antitumor Activity of the Anti-PD-1 Monoclonal Antibody REGN2810 Alone or in Combination with REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with B-Lymphoid Malignancies

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) after Treatment with Nivolumab for Relapsed/Refractory Hodgkin Lymphoma

Single-Agent MOR208 in Relapsed or Refractory (R-R) Non-Hodgkin's Lymphoma (NHL): Results from Diffuse Large B-Cell Lymphoma (DLBCL) and Indolent NHL Subgroups of a Phase IIa Study

Phase IIa Study of Single-Agent MOR208 in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Gene Rearrangements and Other Molecular Features in Aggressive B-Cell Lymphomas of Patients with and without HIV-Infection

A Phase IIa, Open-Label, Multicenter Study of Single-Agent MOR00208, an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma

PLCG1 mutations in cutaneous T-cell lymphomas

Risk Adapted-High Dose Therapies Modulate the Impact of Biological Classification in Diffuse Large B Cell Lymphoma Prognosis. Analysis of Biological Markers in Patients From Clinical Trials in Geltamo and Gotel Spanish Collaborative Groups.

Mutations in PLCG1 Is a Frequent Event in Cutaneous T-Cell Lymphomas

A Prospective Study of Cardiotoxicity In Non-Hodgkin Lymphoma Patients with RAPID-Infusion Rituximab

Treatment of Good Prognosis CD20+ Large-Cell Lymphomas in Patients Aged 65 to 80, with 3 Cycles of R-CHOP14 Followed by An Injection of 90Y Ibritumomab Tiuxetan

Clinical Significance of the Presence of Occult CNS Involvement Assessed by Cytofluorometry in Patients with Non Hodgkin’s Lymphoma and High Risk of CNS Relapse

Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma

Up-Front Treatment of Diffuse Large-B Cell Lymphoma (DLBCL) in Elderly Patients with Rituximab in Combination with CHOP-Like Chemotherapy: A Multicenter Study on the Current Clinical Management.

Treatment with Rituximab, CHOP and Highly Active Antiretroviral Therapy (HAART) in AIDS-Related Diffuse Large B-Cell Lymphomas (DLBCL). Study of 60 Patients.

An IELSG International Survey of Primary Effusion Lymphoma (PEL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only